Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19196890 | 0.90 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL19196883 | 0.88 | TLR7 (0.87) | TLR7TLR8 | |
| SCHEMBL18116590 | 0.87 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL30870440 | 0.85 | TLR7 (0.78) | TLR7TLR8 | |
| SCHEMBL13837354 | 0.84 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL30577190 | 0.84 | TLR7 (1.00) | TLR7TLR8 | |
| Hydrochloric Acid SCHEMBL15881955 | 0.83 | TLR7 (0.98) | TLR7TLR8 | |
| SCHEMBL30870449 | 0.83 | TLR7 (0.77) | TLR7TLR8 | |
| SCHEMBL19196887 | 0.83 | TLR7 (0.87) | TLR7TLR8 | |
| SCHEMBL13837232 | 0.82 | TLR7 (1.00) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565282-A1 | IMMUNOSTIMULATORY ANTI-PD-L1-DRUG CONJUGATES | Seagen Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025103490-A1 | N-OXIDE IMMUNE AGONISTS ACTIVATION BY RADIOTHERAPY | Beijing Changping Laboratory (CN) | 2025-05-22 | — | — | WO | disclosed |
| US-20250090875-A9 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2025-03-20 | — | — | US | disclosed |
| US-20240165251-A1 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | SEAGEN INC (US) | 2024-05-23 | — | — | US | disclosed |
| WO-2024030577-A1 | IMMUNOSTIMULATORY ANTI-PD-L1-DRUG CONJUGATES | SEAGEN INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-4288109-A1 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | Seagen Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022170002-A1 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | SEAGEN INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090875-A9 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | CD47, FCGR2A, ICOS | TLR7 154/4885TLR8 41/4885 |
| US-20240165251-A1 | IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES | CD47, FCGR2A, ICOS | TLR7 154/4885TLR8 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.